Delay discounting in Parkinson's disease: A systematic review and meta-analysis

Paola Pennisi; Mohammad A Salehinejad; Aurora M Corso; Emanuele M Merlo; Alessio Avenanti; Carmelo M Vicario

doi:10.1016/j.bbr.2022.114101

Delay discounting in Parkinson's disease: A systematic review and meta-analysis

Behav Brain Res. 2023 Jan 5:436:114101. doi: 10.1016/j.bbr.2022.114101. Epub 2022 Sep 7.

Authors

Paola Pennisi¹, Mohammad A Salehinejad², Aurora M Corso³, Emanuele M Merlo⁴, Alessio Avenanti⁵, Carmelo M Vicario⁶

Affiliations

¹ Department of Adult and Childhood Human Pathology "Gaetano Barresi", University of Messina, 98125 Messina, Italy. Electronic address: ppennisi@unime.it.
² Leibniz Research Centre for Working Environment and Human Factors, Department of Psychology and Neurosciences, 44139 Dortmund, Germany.
³ Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy.
⁴ Department of Adult and Childhood Human Pathology "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
⁵ Center for Studies and Research in Cognitive Neuroscience, Department of Psychology "Renzo Canestrari", Alma Mater Studiorum Università di Bologna, Cesena Campus, 47521 Cesena, Italy; Neuropsicology and Cognitive Neuroscience Research Center (CINPSI Neurocog), Universidad Católica del Maule, 3460000 Talca, Chile.
⁶ Department of Cognitive Sciences, Psychology, Education and Cultural Studies, University of Messina, 98122 Messina, Italy. Electronic address: cvicario@unime.it.

PMID: 36087861
DOI: 10.1016/j.bbr.2022.114101

Abstract

Delay discounting refers to the depreciation of the value of a reward as a function of the time it takes to obtain it. Growing evidence shows altered delay discounting in several pathological conditions, including neurological disorders. Here, we conducted a systematic review and meta-analysis of the published literature on delay discounting (DD) in Parkinson's Disease (PD). We found steeper DD in patients with PD, compared to healthy controls, both in "on" and "off" dopaminergic medication. These results confirm altered DD in PD and suggest an independent influence of the dopaminergic medication and the clinical condition itself on it. Also the effect of impulse control disorder and of pharmacological treatments are analysed.

Keywords: Dopaminergic medication; Impulsivity; Parkinson’s disease; Steeper delay discounting.

Publication types

Meta-Analysis
Review
Systematic Review
Research Support, Non-U.S. Gov't

MeSH terms

Delay Discounting*
Disruptive, Impulse Control, and Conduct Disorders*
Dopamine Agents / therapeutic use
Humans
Parkinson Disease* / drug therapy
Reward

Substances

Dopamine Agents